Products
Bortrezol®
Pharmacotherapeutic group
Antineoplastic drugInternational name
BortezomibDosage form
lyophilizate for preparation of solution for intravenous and subcutaneous administrationHighly selective reversible 26S proteasome inhibitor, a modified boric acid. 26S proteasome is located both the cytosol and nucleus of all eukaryotic cells and is a key element catalyzing degradation of main proteins involved in regulation of the cellular life cycle. Bortezomib inhibits the chymotrypsin-like activity of the 26S proteasome, blocks proteolysis and ultimately results in apoptosis.
Myeloma cells are up to 1,000-fold more sensitive to apoptosis induced by bortezomib than normal plasma cells.
Bortezomib causes reduction of tumour growth in vivo in many experimental tumour models, including multiple myeloma.